Clinical Trials | November 13, 2025
Philogen updates on Fibromun clinical study developments
FIBROSARC did not meet its primary PFS endpoint in the final analysi
FIBROSARC did not meet its primary PFS endpoint in the final analysi
The high-performance polymer’s transparency and biocompatibility support precise implantation and long-term reliability
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
The inclusion of broad-spectrum sunscreen in the WHO EML and EMLc follows an application submitted in November 2024 by the Global Albinism Alliance
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
Subscribe To Our Newsletter & Stay Updated
